Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DHC PLUS vs ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DHC PLUS is a combination of codeine (an opioid agonist) and homatropine (an anticholinergic). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. Homatropine antagonizes muscarinic acetylcholine receptors, reducing GI motility and secretions, which may decrease opioid-induced nausea and vomiting.
Fexofenadine is a selective peripheral H1-receptor antagonist; pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Relief of acute moderate pain in adults,Off-label: management of diarrhea
Relief of symptoms associated with seasonal allergic rhinitis and nasal congestion in adults and children 12 years and older
1-2 tablets (dihydrocodeine 40 mg/paracetamol 500 mg per tablet) orally every 4-6 hours as needed, maximum 8 tablets per day.
Adults and children 12 years and older: 1 tablet (fexofenadine 60 mg/pseudoephedrine 120 mg) orally every 12 hours with water. Do not exceed 2 tablets in 24 hours.
3.5-5 hours for dihydrocodeine; prolonged in hepatic impairment (up to 8-10 hours) and may require dose adjustment.
Fexofenadine: 14.4 hours in healthy adults (range 11-15 h); pseudoephedrine: 5-8 hours (p H-dependent urinary excretion may prolong to 14-16 h in alkaline urine).
Codeine is metabolized by CYP2D6 to morphine (active), and by CYP3A4 to norcodeine. Homatropine is metabolized via ester hydrolysis and N-demethylation. Both are excreted renally.
Fexofenadine is minimally metabolized by the liver (≤5% via CYP3A4); pseudoephedrine is partially metabolized by hepatic N-demethylation and undergoes renal excretion.
Renal: ~90% as glucuronide conjugates, with 10% as unchanged dihydrocodeine and 5-10% as nordihydrocodeine; biliary/fecal: <5%.
Fexofenadine: 95% excreted unchanged in feces (biliary) and 5% in urine. Pseudoephedrine: 90% excreted unchanged in urine; remainder undergoes hepatic N-demethylation.
20-30% bound to albumin.
Fexofenadine: 60-70% bound to plasma proteins (albumin and α1-acid glycoprotein). Pseudoephedrine: negligible binding (<5%).
1.5 L/kg; reflects moderate tissue distribution due to lipophilicity.
Fexofenadine: 3.3 L/kg (large Vd, extensive tissue distribution); pseudoephedrine: 2.6-3.5 L/kg (distributes into body water).
Oral: ~60-70% due to first-pass metabolism; subcutaneous: ~80-90%; rectal: ~70-80%.
Fexofenadine: 33% oral bioavailability (first-pass effect minimal, but absorption incomplete). Pseudoephedrine: ~90% oral bioavailability.
GFR 30-50 m L/min: Administer every 6-8 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Avoid or use with extreme caution, reduce dose by 50% and monitor for toxicity.
Contraindicated in severe renal impairment (Cr Cl < 30 m L/min). For mild to moderate impairment (Cr Cl 30-80 m L/min): fexofenadine dose adjustment recommended (not to exceed 60 mg once daily), but pseudoephedrine accumulation may occur; use alternative product. Not studied in ESRD.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% and extend interval to every 8 hours; Child-Pugh Class C: Avoid use due to risk of paracetamol hepatotoxicity and dihydrocodeine accumulation.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); caution.
Not recommended for children under 12 years of age. For adolescents (12-18 years): Same adult dosing based on weight, typically 1 tablet every 4-6 hours, maximum 4 tablets per day.
Children under 12 years: not recommended. For children ≥12 years: same as adult dosing: 1 tablet every 12 hours with water.
Initiate with lowest effective dose, 1 tablet every 6-8 hours; maximum 4 tablets per day; monitor for CNS depression and constipation.
Elderly patients may be more sensitive to CNS effects and anticholinergic effects of pseudoephedrine. Not recommended due to increased risk of adverse reactions; consider alternative therapy. If used, monitor closely.
Warning: Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; interactions with alcohol and CNS depressants; risk of medication errors with codeine; risks from concomitant use with benzodiazepines or other CNS depressants; and risks of use in children under 12 years, and in adolescents with certain respiratory conditions.
None.
Risk of respiratory depression,CYP2D6 ultrarapid metabolizers: increased toxicity,Anticholinergic effects (e.g., urinary retention, constipation),Use caution in elderly, renal/hepatic impairment,Avoid in patients with severe respiratory conditions
Cardiovascular effects: hypertension, arrhythmias, palpitations, tachycardia, myocardial infarction, stroke (especially with pre-existing cardiovascular disease or concomitant use with other sympathomimetics).,Central nervous system stimulation: nervousness, dizziness, insomnia, tremor, seizures (may be exacerbated in patients with seizure disorders).,Increased intraocular pressure: contraindicated in narrow-angle glaucoma.,Urinary retention: use with caution in patients with prostate hypertrophy or obstructive uropathy.,Thyroid disorders: may aggravate hyperthyroidism; use with caution.,Diabetes mellitus: may increase blood glucose; monitor in diabetic patients.,Acute allergic reactions: discontinue if severe hypersensitivity occurs.,Renal impairment: fexofenadine clearance reduced; avoid use in severe renal impairment (Cr Cl <30 m L/min).,Elderly: more sensitive to adverse effects; use with caution.,Drug interactions: MAO inhibitors (hypertensive crisis); antihypertensives (reduced effect); alcohol/CNS depressants (additive effects).
Hypersensitivity to codeine, homatropine, or any component,Significant respiratory depression,Acute or severe bronchial asthma,Paralytic ileus,Children under 12 years (codeine)
Hypersensitivity to fexofenadine, pseudoephedrine, or any component of the formulation.,Severe hypertension or coronary artery disease.,Narrow-angle glaucoma.,Urinary retention (e.g., due to bladder neck obstruction or prostatic hyperplasia).,Severe renal impairment (Cr Cl <30 m L/min).,Concurrent use or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis).
Avoid alcohol as it increases sedation and hepatotoxicity risk. High-fat meals may delay absorption but not significantly alter efficacy.
Avoid alcohol, which can increase drowsiness. Grapefruit juice may reduce absorption of fexofenadine; avoid concurrent intake. Taking with high-fat meal may slow absorption but not affect overall efficacy.
DHC PLUS (dihydrocodeine/paracetamol): First trimester risk of neural tube defects with paracetamol use is low but not zero; dihydrocodeine may cause respiratory depression in neonate if used near term. Chronic use in third trimester can lead to neonatal opioid withdrawal syndrome.
FDA Pregnancy Category C. First trimester: Animal studies show teratogenic effects at high doses of fexofenadine; pseudoephedrine may cause reduced uterine blood flow. Second and third trimesters: Risk of uterine contractions and fetal hypoxia due to pseudoephedrine vasoconstriction; avoid in preeclampsia.
Dihydrocodeine and paracetamol are excreted in breast milk in low amounts. M/P ratio for dihydrocodeine is approximately 0.5-1.0. Use with caution; monitor infant for sedation and respiratory depression. Paracetamol is considered compatible with breastfeeding.
Fexofenadine: low excretion in breast milk (M/P ratio not established); pseudoephedrine: excreted in milk, may cause irritability and sleep disturbances in infants. Use caution, consider risk-benefit.
Increased clearance of dihydrocodeine in pregnancy may require dose adjustment; however, avoid use if possible. Paracetamol pharmacokinetics are minimally altered; standard dosing is acceptable. Short-term use only; avoid high doses of paracetamol (>2g/day) in third trimester.
No specific dose adjustments recommended; use lowest effective dose for shortest duration due to altered pharmacokinetics (increased plasma volume, decreased GFR).
DHC PLUS contains dihydrocodeine and paracetamol. Avoid in CYP2D6 ultra-rapid metabolizers due to morphine toxicity risk. Use with caution in patients with respiratory compromise, as dihydrocodeine can cause respiratory depression. Monitor liver function with prolonged paracetamol use.
Allegra-D 12 Hour contains fexofenadine (antihistamine) and pseudoephedrine (decongestant). Pseudoephedrine can cause insomnia, so advise taking the last dose early in the evening. Avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Use with caution in hyperthyroidism, diabetes, and prostatic hypertrophy. Do not exceed recommended dose; extended-release formulation must be swallowed whole.
Do not exceed recommended dose due to paracetamol hepatotoxicity risk.,Avoid alcohol while taking this medication.,May cause drowsiness or dizziness; avoid driving or operating machinery.,Take with food if gastrointestinal upset occurs.,Do not crush or chew extended-release formulations.
Take this medication by mouth with or without food, usually every 12 hours.,Swallow the tablet whole; do not crush, chew, or break it.,Do not take more than 2 tablets in 24 hours.,Avoid taking at bedtime to prevent difficulty sleeping.,Do not take with other products containing pseudoephedrine or other decongestants.,Stop use and ask a doctor if symptoms do not improve within 7 days or are accompanied by fever.,Keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DHC PLUS vs ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, answered by our medical review team.
DHC PLUS is a Antihistamine-Decongestant that works by DHC PLUS is a combination of codeine (an opioid agonist) and homatropine (an anticholinergic). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. Homatropine antagonizes muscarinic acetylcholine receptors, reducing GI motility and secretions, which may decrease opioid-induced nausea and vomiting.. ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is a Antihistamine-Decongestant Combination that works by Fexofenadine is a selective peripheral H1-receptor antagonist; pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DHC PLUS and ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DHC PLUS is: 1-2 tablets (dihydrocodeine 40 mg/paracetamol 500 mg per tablet) orally every 4-6 hours as needed, maximum 8 tablets per day.. The standard adult dose of ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is: Adults and children 12 years and older: 1 tablet (fexofenadine 60 mg/pseudoephedrine 120 mg) orally every 12 hours with water. Do not exceed 2 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DHC PLUS and ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DHC PLUS is classified as Category C. DHC PLUS (dihydrocodeine/paracetamol): First trimester risk of neural tube defects with paracetamol use is low but not zero; dihydrocodeine may cause respiratory depression in neon. ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show teratogenic effects at high doses of fexofenadine; pseudoephedrine may cause reduced uterine blood flow. Second and t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.